Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONES 4: Solriamfetol in OSA (Randomized Withdrawal)
NCT02348619Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2015
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
A Phase 3 trial of solriamfetol in obstructive sleep apnea (OSA), sponsored by Jazz Pharmaceuticals plc. Started May 2015; status: completed.
02
Drugs
solriamfetol
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT02348619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348619.